Catalytic antibodies: Balancing between Dr. Jekyll and Mr. Hyde

BioEssays

Volumn 31, Issue 11, 2009, Pages 1161-1171

  Belogurov Jr , Alexey ^a   Kozyr, Arina ^a   Ponomarenko, Natalia ^a   Gabibov, Alexander ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Abzymes; Anti DNA antibodies; Autoimmunity; Catalytic vaccines; Transition state

Indexed keywords

ABZYME; BLOOD CLOTTING FACTOR 8 ANTIBODY; CATALYTIC ANTIBODY; DNA; DNA VACCINE; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN M ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BIOCATALYST; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HYDROLYSIS; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATION; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SEPSIS; THYROIDITIS;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, CATALYTIC; AUTOIMMUNITY; BIOCHEMISTRY; DIABETES MELLITUS; FACTOR VIII; HUMANS; IMMUNOGLOBULINS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; PROTEIN ENGINEERING; SEPSIS; THYROIDITIS; VACCINES;

EID: 70549085026     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.200900020     Document Type: Review

References (114)

1. Fisher E. 1894. Berichte Dtsh Chem Ges 27: 2968.
2. Jenks WP. 1969. Catalysis in Chemistry and Enzymology. New York: McGraw-Hill.
3. Jerne NK. 1974. Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389
4. Pauling L. 1948. Chemical achievement and hope for the future. Am Sci 36: 51-58
5. Friboulet A, Izadyar L, Avalle B, et al. 1995. Antiidiotypic antibodies as functional internal images of enzyme-active sites. Ann N Y Acad Sci 750: 265-270
6. Shuster AM, Gololobov GV, Kvashuk OA, et al. 1992. DNA hydrolyzing autoantibodies. Science 256: 665-667
7. Raso V, Stollar BD. 1975. The antibody-enzyme analogy. Comparison of enzymes and antibodies specific for phosphopyridoxyltyrosine. Biochemistry 14: 591-599
8. Green BS. 1989. Monoclonal antibodies as catalysts and templates for organic chemical reactions. Adv Biotechnol Process 11: 359-393
9. Kohen F, Kim JB, Lindner HR, et al. 1980. Monoclonal immunoglobulin G augments hydrolysis of an ester of the homologous hapten: an esterase-like activity of the antibody-containing site? FEBS Lett 111: 427-431
10. Lerner RA, Barbas CF III, Janda KD. 1996. Making enzymes. Harvey Lect 92: 1-40.
11. Shokat KM, Leumann CJ, Sugasawara R, et al. 1989. A new strategy for the generation of catalytic antibodies. Nature 338: 269-271 (Pubitemid 19086931)
12. Hilvert D. 2000. Critical analysis of antibody catalysis. Annu Rev Biochem 69: 751-793
13. Janda KD. 1993. Catalytic antibodies: the rerouting of chemical reactions. Biochem Soc Trans 21: 1090-1095 (Pubitemid 24011793)
14. Tramontano A, Janda KD, Lerner RA. 1986. Catalytic antibodies. Science 234: 1566-1570
15. Janda KD, Schloeder D, Benkovic SJ, et al. 1988. Induction of an antibody that catalyzes the hydrolysis of an amide bond. Science 241: 1188-1191 (Pubitemid 18215996)
16. Paul S, Volle DJ, Beach CM, et al. 1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158-1162 (Pubitemid 19170484)
17. Gololobov GV, Chernova EA, Schourov DV, et al. 1995. Cleavage of supercoiled plasmid DNA by autoantibody Fab fragment: application of the flow linear dichroism technique. Proc Natl Acad Sci U S A 92: 254-257
18. Izadyar L, Friboulet A, Remy MH, et al. 1993. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci U S A 90: 8876-8880 (Pubitemid 23306413)
19. Paul S, Volle DJ, Mei S. 1990. Affinity chromatography of catalytic autoantibody to vasoactive intestinal peptide. J Immunol 145: 1196-1199 (Pubitemid 20258723)
20. Bronshtein IB, Shuster AM, Shevchenko LV, et al. 1989. Topoisomerase I from human placenta. Functional activity of products of expression of cloned cDNA fragments. Mol Biol (Mosk) 23: 1553-1557
21. Bronshtein IB, Shuster AM, Gololobov GV, et al. 1992. DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Lett 314: 259-263
22. Avalle B, Thomas D, Friboulet A. 1998. Functionalmimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams. FASEB J 12: 1055-1060 (Pubitemid 28359587)
23. Paul S. 1994. Catalytic activity of anti-ground state antibodies, antibody subunits, and human autoantibodies. Appl Biochem Biotechnol 47: 241- 53; discussion 253-1245
24. Rodkey LS, Gololobov G, Rumbley CA, et al. 2000. DNA hydrolysis by monoclonal autoantibody BV 04-01. Appl Biochem Biotechnol. 83: 95- 103; discussion 103-5, 145-153
25. Gololobov GV, Rumbley CA, Rumbley JN, et al. 1997. DNA hydrolysis by monoclonal anti-ssDNA autoantibody BV 04-01: origins of catalytic activity. Mol Immunol 34: 1083-1093
26. Gololobov GV, Mikhalap SV, Starov AV, et al. 1994. DNA-protein complexes. Natural targets for DNA-hydrolyzing antibodies. Appl Biochem Biotechnol 47: 305-14; discussion 314-1305
27. Kozyr AV, Kolesnikov AV, Aleksandrova ES, et al. 1998. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol 75: 45-61.
28. Homberger HP. 1989. Bent DNA is a structural feature of scaffoldattached regions in Drosophila melanogaster interphase nuclei. Chromosoma 98: 99-104.
29. Stewart JD, Benkovic SJ. 1995. Transition-state stabilization as a measure of the efficiency of antibody catalysis. Nature 375: 388-391
30. Tonello F, Seveso M, Marin O, et al. 2002. Screening inhibitors of anthrax lethal factor. Nature 418: 386. (Pubitemid 34826833)
31. Gao QS, Sun M, Rees AR, et al. 1995. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 253: 658-664
32. Kolesnikov AV, Kozyr AV, Alexandrova ES, et al. 2000. Enzyme mimicry by the antiidiotypic antibody approach. Proc Natl Acad Sci U S A 97: 13526-13531
33. Ramsland PA, Terzyan SS, Cloud G, et al. 2006. Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. Biochem J 395: 473-481
34. Erhan S, Greller LD. 1974. Do immunoglobulins have proteolytic activity? Nature 251: 353-355
35. Paul S, Li L, Kalaga R, et al. 1995. Natural catalytic antibodies: peptidehydrolyzing activities of Bence Jones proteins and VL fragment. J Biol Chem 270: 15257-15261
36. Ponomarenko NA, Durova OM, Vorobiev II, et al. 2002. Catalytic antibodies in clinical and experimental pathology: human and mouse models. J Immunol Methods 269: 197-211.
37. Taguchi H, Planque S, Sapparapu G, et al. 2008. Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 283: 36724-36733
38. Reshetnyak AV, Armentano MF, Ponomarenko NA, et al. 2007. Routes to covalent catalysis by reactive selection for nascent protein nucleophiles. J Am Chem Soc 129: 16175-16182
39. Johnson G, Moore SW. 2009. Investigations into the development of catalytic activity in anti-acetylcholinesterase idiotypic and anti-idiotypic antibodies. J Mol Recognit 22: 188-196
40. Ponomarenko NA, Pillet D, Paon M, et al. 2007. Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry 46: 14598-14609 (Pubitemid 350276365)
41. Vlassov A, Florentz C, Helm M, et al. 1998. Characterization and selectivity of catalytic antibodies from human serum with RNase activity. Nucleic Acids Res 26: 5243-5250 (Pubitemid 28542720)
42. Wentworth P Jr., Liu Y, Wentworth AD, et al. 1998. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis. Proc Natl Acad Sci U S A 95: 5971-5975 (Pubitemid 28248948)
43. Kim YR, Kim JS, Lee SH, et al. 2006. Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. J Biol Chem 281: 15287-15295
44. Lee EJ, Jang EJ, Lee E, et al. 2007. Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA. Bioorg Med Chem 15: 2016-2023 (Pubitemid 46188403)
45. Kozyr AV, Kolesnikov AV, Zelenova NA, et al. 2000. Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity. Appl Biochem Biotechnol 83: 255-68; discussion 268-259, 297-313.
46. Gololobov GV, Bogomolova AE, Iadav RP, et al. 1993. Isolation and characteristics of catalytic antibodies to DNA in systemic lupus erythematosis. Biokhimiia 58: 313-318
47. Kozyr AV, Sashchenko LP, Kolesnikov AV, et al. 2002. Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett 80: 41-47.
48. Sashchenko LP, Khaidukov SV, Kozyr AV, et al. 2001. Caspase-dependent cytotoxicity of anti-DNA autoantibodies. Dokl Biochem Biophys 380: 313-315
49. Foster MH, Kieber-Emmons T, Ohliger M, et al. 1994. Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies. Immunol Res 13: 186-206.
50. Parkhomenko TA, Odintsova ES, Buneva VN, et al. 2008. DNA-hydrolyzing activity of IgG antibodies from the sera of patients with diseases caused by different bacterial infections. J Cell Mol Med Doi: 10.1111/j.1582-4934.2008. 00441.x
51. Jaffa AA, Durazo-Arvizu R, Zheng D, et al. 2003. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 52: 1215-1221 (Pubitemid 36523359)
52. Flakoll PJ, Hill JO, Abumrad NN. 1993. Acute hyperglycemia enhances proteolysis in normal man. Am J Physiol 265: E715-21.
53. Pagetta A, Tramentozzi E, Corbetti L, et al. 2007. Characterization of immune complexes of idiotypic catalytic and anti-idiotypic inhibitory antibodies in plasma of type 1 diabetic subjects. Mol Immunol 44: 2870-2883 (Pubitemid 46412495)
54. Menoret A, Li Z, Niswonger ML, et al. 2001. An endoplasmic reticulum protein implicated in chaperoning peptides to major histocompatibility of class I is an aminopeptidase. J Biol Chem 276: 33313-33318 (Pubitemid 37384537)
55. Li L, Paul S, Tyutyulkova S, et al. 1995. Catalytic activity of anti-thyroglobulin antibodies. J Immunol 154: 3328-3332
56. Paul S, Li L, Kalaga R, et al. 1997. Characterization of thyroglobulin-directed and polyreactive catalytic antibodies in autoimmune disease. J Immunol 159: 1530-1536 (Pubitemid 127484134)
57. White GC II, Shoemaker CB. 1989. Factor VIII gene and hemophilia A. Blood 73: 1-12.
58. Ehrenforth S, Kreuz W, Scharrer I, et al. 1992. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594-598
59. Lacroix-Desmazes S, Moreau A, Sooryanarayana, et al. 1999. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 5: 1044-1047 (Pubitemid 29439576)
60. Lacroix-Desmazes S, Bayry J, Misra N, et al. 2002. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 346: 662-667 (Pubitemid 34815870)
61. Wootla B, Dasgupta S, Dimitrov JD, et al. 2008. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 180: 7714-7720
62. Degen SJ, Sun WY. 1998. The biology of prothrombin. Crit Rev Eukaryot Gene Expr 8: 203-224
63. Bertolaccini ML, Atsumi T, KhamashtaMA, et al. 1998. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 25: 1104-1108 (Pubitemid 28350883)
64. Palosuo T, Virtamo J, Haukka J, et al. 1997. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - A nested case-control study. Thromb Haemostasis 78: 1178-1182 (Pubitemid 27464582)
65. Thiagarajan P, Dannenbring R, Matsuura K, et al. 2000. Monoclonal antibody light chain with prothrombinase activity. Biochemistry 39: 6459-6465 (Pubitemid 30347151)
66. Lacroix-Desmazes S, Bayry J, Kaveri SV, et al. 2005. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci U S A 102: 4109-4113 (Pubitemid 40388563)
67. Barrera GJ, Portillo R, Mijares A, et al. 2009. Immunoglobulin A with protease activity secreted in human milk activates PAR-2 receptors, of intestinal epithelial cells HT-29, and promotes beta-defensin-2 expression. Immunol Lett 123: 52-59
68. Kit Y, Semenov DV, Nevinsky GA. 1996. Phosphorylation of different human milk proteins by human catalytic secretory immunoglobulin A. Biochem Mol Biol Int 39: 521-527 (Pubitemid 26254598)
69. Nevinsky GA, Buneva VN. 2003. Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases. J Cell Mol Med 7: 265-276 (Pubitemid 37372046)
70. Wentworth P Jr., Jones LH, Wentworth AD, et al. 2001. Antibody catalysis of the oxidation of water. Science 293: 1806-1811
71. Wentworth P Jr., McDunn JE, Wentworth AD, et al. 2002. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science 298: 2195-2199
72. Wentworth P Jr., Wentworth AD, Zhu X, et al. 2003. Evidence for the production of trioxygen species during antibody-catalyzed chemical modification of antigens. Proc Natl Acad Sci U S A 100: 1490-1493 (Pubitemid 36254473)
73. Zhu X, Wentworth P Jr., Wentworth AD, et al. 2004. Probing the antibody-catalyzed water-oxidation pathway at atomic resolution. Proc Natl Acad Sci U S A 101: 2247-2252 (Pubitemid 38269297)
74. Nieva J, Kerwin L, Wentworth AD, et al. 2006. Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. Immunol Lett 103: 33-38 (Pubitemid 43162943)
75. Peng KJ, Huang YS, An LN, et al. 2006. Effect of ozone produced from antibody-catalyzed water oxidation on pathogenesis of atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 38: 417-422
76. Wang Y, Qiao B, Han X, et al. 2006. Autoantibodies closely relate to the elevation level of in vivo hydrogen peroxide and tissue damage in systemic lupus erythematosus. DNA Cell Biol 25: 563-570 (Pubitemid 46150667)
77. Babior BM, Takeuchi C, Ruedi J, et al. 2003. Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci U S A 100: 3031-3034 (Pubitemid 36358199)
78. Parren PW, Leusen JH, van de Winkel JG. 2003. Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? Trends Immunol 24: 467-469
79. Klyubin I, Walsh DM, Lemere CA, et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11: 556-561 (Pubitemid 40685979)
80. Dodel RC, Du Y, Depboylu C, et al. 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatr 75: 1472-1474 (Pubitemid 39279821)
81. Schenk D, Hagen M, Seubert P. 2004. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 16: 599-606.
82. Rangan SK, Liu R, Brune D, et al. 2003. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry 42: 14328-14334 (Pubitemid 37499430)
83. Paul S, Nishiyama Y, Planque S, et al. 2005. Antibodies as defensive enzymes. Springer Semin Immunopathol 26: 485-503.
84. Ponomarenko NA, Durova OM, Vorobiev II, et al. 2006. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett 103: 45-50.
85. Polosukhina DI, Kanyshkova TG, Doronin BM, et al. 2004. Hydrolysis of myelin basic protein by polyclonal catalytic IgGs from the sera of patients with multiple sclerosis. J Cell Mol Med 8: 359-368
86. Ponomarenko NA, Durova OM, Vorobiev II, et al. 2006. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A 103: 281-286
87. Belogurov AA, Kurkova IN, Misikov VK, et al. 2007. Substrate speci- ficity of catalytic autoantibodies in neurodegenerative processes. Dokl Biochem Biophys 413: 61-64
88. Belogurov AA Jr., Kurkova IN, Friboulet A, et al. 2008. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 180: 1258-1267
89. D'Souza CA, Moscarello MA. 2006. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem Res 31: 1045-1054
90. D'Souza CA, Wood DD, She YM, et al. 2005. Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. Biochemistry 44: 12905-12913
91. Medveczky P, Antal J, Patthy A, et al. 2006. Myelin basic protein, an autoantigen in multiple sclerosis, is selectively processed by human trypsin 4. FEBS Lett 580: 545-552 (Pubitemid 43089684)
92. Pritzker LB, Joshi S, Gowan JJ, et al. 2000. Deimination ofmyelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 39: 5374-5381
93. Musse AA, Boggs JM, Harauz G. 2006. Deimination of membranebound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci U S A 103: 4422-4427
94. Husted C. 2006. Structural insight into the role of myelin basic protein in multiple sclerosis. Proc Natl Acad Sci U S A 103: 4339-4340
95. Paul S, Karle S, Planque S, et al. 2004. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 279: 39611-39619 (Pubitemid 39258228)
96. Hifumi E, Mitsuda Y, Ohara K, et al. 2002. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. J Immunol Methods 269: 283-298
97. Gorny MK, Stamatatos L, Volsky B, et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 79: 5232-5237 (Pubitemid 40464273)
98. Choudhry V, Zhang MY, Sidorov IA, et al. 2007. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363: 79-90. (Pubitemid 46678166)
99. Gach JS, Quendler H, Ferko B, et al. 2008. Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine. Mol Biotechnol 39: 119-125
100. Karle S, Planque S, Nishiyama Y, et al. 2004. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 18: 329-331 (Pubitemid 38253459)
101. Ponomarenko NA, Vorobiev II, Alexandrova ES, et al. 2006. Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry 45: 324-330
102. Wirsching P, Ashley JA, Lo CH, et al. 1995. Reactive immunization. Science 270: 1775-1782
103. Gabibov AG, Friboulet A, Thomas D, et al. 2002. Antibody proteases: induction of catalytic response. Biochemistry (Mosc) 67: 1168-1179 (Pubitemid 35468958)
104. Durova OM, Vorobiev II, Smirnov IV, et al. 2009. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol Immunol Doi:10.1016/j.molimm.2008.12.020
105. Shabat D, Lode HN, Pertl U, et al. 2001. In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci U S A 98: 7528-7533
106. Aktas O, Waiczies S, Zipp F. 2007. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol 184: 17-26. (Pubitemid 46365988)
107. Smith BM. 2008. Catalytic methods for the destruction of chemical warfare agents under ambient conditions. Chem Soc Rev 37: 470-478
108. Dias S, Jovic F, Renard PY, et al. 2002. Immunologically driven chemical engineering of antibodies for catalytic activity. J Immunol Methods 269: 81-98.
109. Spivak DA, Hoffman TZ, Moore AH, et al. 1999. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis. Bioorg Med Chem 7: 1145-1150
110. Wentworth P, Datta A, Blakey D, et al. 1996. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Proc Natl Acad Sci U S A 93: 799-803.
111. Xu Y, Hixon MS, Yamamoto N, et al. 2007. Antibody-catalyzed anaerobic destruction of methamphetamine. Proc Natl Acad Sci U S A 104: 3681-3686
112. Landry DW. 1997. Immunotherapy for cocaine addiction. Sci Am 276: 42-45
113. McKenzie KM, Mee JM, Rogers CJ, et al. 2007. Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 365: 722-731
114. Vayron P, Renard PY, Taran F, et al. 2000. Toward antibody-catalyzed hydrolysis of organophosphorus poisons. Proc Natl Acad Sci U S A 97: 7058-7063 (Pubitemid 30431416)